Providing access to highly effective therapies in the communities where patients live is critical to improving outcomes. Safety of bsabs and CAR-T is continuously improving and we need partnerships to bring these therapies to more community oncology centers. #HemOnc #lymsm #MedSky

VJHemOnc@vjhemonc.bsky.social · last yr.

🎥 At #iwCART25, @krishpatelmd.bsky.social‬, Tara Graff, & Caron Jacobson shared their perspectives on how to improve access & delivery of T-cell engaging therapies (CAR-T and bispecifics) in the community. Watch the discussion here: 👉 buff.ly/4s5IV1D #HemOnc #CARTCell #ImmunoOnc #MedSky

SCRI expert, Dr. Stephen Strickland presented interim results for SENTI-202 at #AACR2025. This CAR NK cell therapy shows potential in treating relapsed AML, with several patients achieving complete remission. Read more www.usnews.com/news/health-... #CancerResearch #CAR_NK_Therapy #AML #USNews

This is so incredibly sad for cancer and specifically cell and gene therapy. I am profoundly grateful to Peter for his service, collaboration and dedication through an incredibly impactful career. CAR-T therapies would not be where they are without his efforts. www.wsj.com/politics/top...

We owe him much for his leadership at CBER during a period of remarkable therapeutic advances. The havoc caused by this administration will have a devastating impact for years. www.washingtonpost.com/politics/202...

RFK Jr. forces out Peter Marks, FDA’s top vaccine scientist

Marks, an architect of Operation Warp Speed for coronavirus vaccines, warned that a measles outbreak shows how confidence in science is being “undermined.”

washingtonpost.com

So many exciting developments in MCL in the past few years. Much more to come also with a lot of exciting clinical trials and investigational therapies being developed. #lymsm #HemeSky

VJHemOnc@vjhemonc.bsky.social · 2y ago

Hear the updates in #MantleCellLymphoma from #ASH24 and key takeaways for community oncologists in our wonderful interview with @krishpatelmd.bsky.social of @scrinetwork.bsky.social! Click here to watch: 👉 buff.ly/4jmisjj 👈 #LYMsm #CTSM #HemOnc #HemeSky @ash.hematology.org

Long awaited…Excited to see our multi-center effort of CD19 allo iPSC CAR-NK in B-cell #lymsm! Impt proof of concept: -very low CRS ✅ -no ICANS ✅ -multi dose off shelf tx ✅ -durable responses in challenging histologies ✅ Lots still to do for the field of CAR-NK www.thelancet.com/journals/lan...

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

FT596 was well tolerated as monotherapy or with rituximab and induced deep and durable responses in patients with indolent and aggressive lymphomas and the RP2D was preliminarily identified to be 1·8 × 109 cells for three doses per cycle. This study supports that cell therapy using iPSC-derived, gene-modified NK cells is a potent platform for cancer treatment and suggests that such a platform might address limitations of currently available immune cell therapies, including manufacturing time, heterogeneity, access, and cost.

thelancet.com

Amazing and very important work for the field. 👏🏽👏🏽👏🏽

Rémy Duléry@remydulery.bsky.social · 2y ago

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

Every year this is how I feel after ASH. A final #ASHaiku Every year it comes ASH conference lights the path Purpose renewed #ASH24 #hematology #HemeSky #lymsm

American Society of Hematology@ash.hematology.org · 2y ago

Are you feeling revitalized? 🎇 #ASH24 has been an incredible reminder of why we do what we do. The knowledge and inspiration gained here will undoubtedly lead to exciting advances as we return home to apply what we've learned. Here's to a fantastic final day in San Diego!☀️ #HemeSky #Hematology

Excited to be at ASH in my new role at SCRI! Stop by our booth to learn about exciting things happening in our network! #ASH24 #lymsm #CancerResearch

Want to hear about the targeting of BTK for the treatment of CLL and NHL? Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov! Click here: 👉https://buff.ly/4f3mR7s👈 #iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma

Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders | VJHemOnc

In this video, Tanya Siddiqi, MD, City of Hope, Duarte, CA, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, and...

buff.ly

On the way to @ash-hematology.bsky.social 2024. Beautiful middle TN sunrise over Cumberland River. Excited for science, collaboration, and all the best of #hematology #hemesky #lymsm #lymsky #ASH2024

A very exciting time to join Sarah Cannon. Cutting edge research in rapidly growing programs.

Looking forward to full study presentation. I like the approach but devil is in the details. Followup is short and mPFS 16 mths R2 control arm not quite performing like AUGMENT (where R2 median pfs 27.6mths at 5yr f/u) but it is a randomized comparison. Are pts higher risk in this study 🤔? #lymsm

Owhofasa Agbedia, MD, MPH, FACP@fasaagbedia.bsky.social · 2y ago

#ASH24 LBA-1 Tafa+Len+R for r/r FL N=548, med fu 14m ⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾 Consistent benefit in all subgrps including POD24 (32% of study)!!, CR 49.4% vs 39.8% ORR 83.5% vs 72.4% Med DOR 21.2m vs 13.6m Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...

Glofi-PolaRCHP 95/97% pfs/os 👀🤯

Ajay Major, MD, MBA@majorajay.bsky.social · 2y ago

Ph2 glofi-RCHOP v glofi-polaRCHP 1L LBCL @mike_dickinson1 - 80 pts, 38% non-GC, 11% DHL - CR: 70% RCHOP, 80% pola - 1-yr PFS/OS: 88/96% R-CHOP, 95/97% pola - no G3-5 CRS, no ICANS - EOT PRs did not progress or converted to CR (cfDNA neg!) Rethink EOT PET with BsAbs? #lymsm